1411. Impact of a Dashboard to Improve Antimicrobial Stewardship in the Largest Not-For-Profit Healthcare System in the United States
Session: Poster Abstract Session: Antimicrobial Stewardship: Interventions
Saturday, October 10, 2015
Room: Poster Hall
Posters
  • Poster-IDSA-Dashboard-15.pdf (300.3 kB)
  • Background: Antimicrobial stewardship plays the most crucial role to control the development of multidrug resistant organisms (MDROs). Given the societal value of antimicrobials and their diminishing effectiveness due to antimicrobial resistance, broad implementation of antimicrobial stewardship programs is critically important. We describe the impact of a dashboard on reduction of antimicrobial pressure at our hospitals located in 23 States compared to the baseline use in 2013 fiscal year (FY).

    Methods: A dashboard on the utilization of broad spectrum and “niche” products was developed to help our facilities to identify areas for improvement to achieve antimicrobial stewardship. Defined daily dose (DDD) per thousand patient days of daptomycin, linezolid, tigecycline, cephalosporins, carbapenems, quinolones, aztreonam are tracked every month and available on the dashboard. System and individual facility average, maximum and minimum DDD/1000 patient days on specific agent/class are available on the intranet.

    Results:

    DDD/1000 patient days for Daptomycin, linezolid, tigecycline, aztreonam, quinolones, cephalosporins, carbapenems were decreased (table ) over two years compared to the baseline in 2013.  Percentage of reduction of targeted agents raneged between 2% to 43% between 2014 and 2015.

    Conclusion:

    We conclude that a dashboard on utilization of board spectrum and niche agents contribute significantly to reduce antimicrobial pressure leading to judicious use and antimicrobial stewardship.

    Table

     

     

    Agent

    Average DDD/1000 Pt Days

    % Increase/ Decrease

    Maximum DDD/1000 Pt Days

    Minimum DDD/1000 Pt Days

    FY 2013

    2014

    2015

    2014 and 2015

    FY 2013

    2014

    2015

    FY 2013

    2014

    2015

    Daptomycin

    14.1

    14.7

    12.7

    (-) 13.61%

    20.9

    21.9

    25.3

    8.5

    9.8

    9.5

    Linezolid

    6.0

    5.8

    3.3

    (-) 43%

    8.3

    8.7

    5.0

    3.1

    3.9

    2.0

    Tigecycline

    2.6

    1.7

    1.3

    (-) 23.52%

    3.7

    2.9

    3.3

    1.6

    0.9

    0.6

    Ceftaroline

    1.5

    1.7

    1.5

    (-) 11.76%

    2.7

    2.5

    2.1

    0.6

    1.1

    1.0

    Aztreonam

    4.2

    3.7

    3.4

    (-) 8.1%

    5.4

    4.7

    5.4

    3.4

    2.6

    2.0

    Quinolones

    205

    201

    185

    (-) 7.9%

    273

    330

    265

    167

    145

    137

    Cephalosporins

    284

    283

    277

    (-)2%

    448

    357

    369

    224

    229

    223

    Carbapenems

    33.3

    30

    29.4

    (-) 2%

    57.3

    34.2

    38.8

    23.2

    26.8

    23.9

    Roy Guharoy, PharmD, MBA1,2, Mohamad G. Fakih, MD, MPH, FIDSA, FSHEA3,4, Jeffrey Seggerman, MBA5, Karen Smethers, Pharm.D.5 and Ann Hendrich, RN, PhD4, (1)Medicine, University of Massachusetts Medical School, Worcester, MA, (2)Care Excellence, Ascension Health, St. Louis, MO, (3)Infection Prevention and Control, St. John Hospital & Medical Center, Grosse Pointe Woods, MI, (4)Care Excellence, Ascension Health, St Louis, MO, (5)Ascension Health, St Louis, MO

    Disclosures:

    R. Guharoy, None

    M. G. Fakih, None

    J. Seggerman, None

    K. Smethers, None

    A. Hendrich, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.